Efficacy and safety of sacubitril‐valsartan in heart failure: a meta‐analysis of randomized controlled trials
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of sacubitril‐valsartan in heart failure: a meta‐analysis of randomized controlled trials
Authors
Keywords
-
Journal
ESC Heart Failure
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-09-26
DOI
10.1002/ehf2.12974
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Heart failure with preserved ejection fraction diagnosis and treatment: An updated review of the evidence
- (2020) Marco Giuseppe Del Buono et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation: The PRIME Study
- (2019) Duk-Hyun Kang et al. CIRCULATION
- Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study
- (2019) Rolf Wachter et al. EUROPEAN JOURNAL OF HEART FAILURE
- Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials
- (2019) Pingping Yang et al. HEART FAILURE REVIEWS
- Sacubitril/valsartan in heart failure with reduced ejection fraction patients: Real world experience on advanced chronic kidney disease, hypotension, and dose escalation
- (2019) Hung-Yu Chang et al. Journal of Cardiology
- Antihypertensive effect of sacubitril/valsartan: a meta-analysis
- (2019) Renato De Vecchis et al. MINERVA CARDIOANGIOLOGICA
- Clinical Outcomes in Patients With Acute Decompensated Heart Failure Randomly Assigned to Sacubitril/Valsartan or Enalapril in the PIONEER-HF Trial
- (2019) David A. Morrow et al. CIRCULATION
- Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction
- (2019) Akshay S. Desai et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction
- (2019) Scott D. Solomon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sacubitril-Valsartan for the treatment of heart failure
- (2019) Marco Giuseppe Del Buono et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Prior Heart Failure Hospitalization, Clinical Outcomes, and Response to Sacubitril/Valsartan Compared with Valsartan in HFpEF
- (2019) Muthiah Vaduganathan et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of Sacubitril/Valsartan Versus Irbesartan in Patients with Chronic Kidney Disease: A Randomised Double-Blind Trial
- (2018) Richard Haynes et al. CIRCULATION
- Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril
- (2018) Orly Vardeny et al. Circulation-Heart Failure
- Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial
- (2018) Milton Packer et al. Lancet Diabetes & Endocrinology
- Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure
- (2018) Eric J. Velazquez et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF
- (2017) Michael Böhm et al. EUROPEAN HEART JOURNAL
- Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in patients with heart failure and reduced ejection fraction: insights from the TITRATION study
- (2017) Michele Senni et al. EUROPEAN JOURNAL OF HEART FAILURE
- Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition
- (2016) Scott A. Hubers et al. CIRCULATION
- Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis
- (2016) Scott D. Solomon et al. EUROPEAN JOURNAL OF HEART FAILURE
- Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction
- (2016) Thomas A. Gaziano et al. JAMA Cardiology
- LCZ696 (Valsartan/Sacubitril) - A Possible New Treatment for Hypertension and Heart Failure
- (2015) Mathilde Borring Andersen et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction
- (2015) Adriaan A. Voors et al. EUROPEAN JOURNAL OF HEART FAILURE
- Angiotensin Receptor Neprilysin Inhibition in Heart Failure: Mechanistic Action and Clinical Impact
- (2015) Jonathan Buggey et al. JOURNAL OF CARDIAC FAILURE
- Secondary Mitral Regurgitation in Heart Failure
- (2015) Anita W. Asgar et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure
- (2014) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Neprilysin and Renin-Angiotensin System Inhibition for the Treatment of Heart Failure
- (2014) Orly Vardeny et al. JACC-Heart Failure
- Heart Disease and Stroke Statistics—2014 Update
- (2013) Alan S. Go et al. CIRCULATION
- Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact
- (2013) John J. V. McMurray et al. EUROPEAN JOURNAL OF HEART FAILURE
- 2013 ACCF/AHA Guideline for the Management of Heart Failure
- (2013) Clyde W. Yancy et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
- (2012) Scott D Solomon et al. LANCET
- Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat
- (2011) Laxminarayan G Hegde et al. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
- Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
- (2010) Luis Miguel Ruilope et al. LANCET
- Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)
- (2009) Jessie Gu et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Rehospitalizations among Patients in the Medicare Fee-for-Service Program
- (2009) Stephen F. Jencks et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema
- (2007) R M Fryer et al. BRITISH JOURNAL OF PHARMACOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started